3-氯苯乙基溴 | 16799-05-6

• 物质功能分类: 有机原料 - 烃类化合物及其衍生物 - 芳香烃
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-氯苯乙基溴
• 中文别名: 1-(2-溴乙基)-3-氟苯；3-氯-1-(2-溴乙基)苯；1-(2-溴乙基)-3-氯苯
• 英文名称: 2-(3-chlorophenyl)ethyl bromide
• 英文别名: 1-(2-bromoethyl)-3-chlorobenzene；3-chlorophenethyl bromide；3-chlorophenylethyl bromide
• CAS: 16799-05-6
• 化学式: C₈H₈BrCl
• 分子量: 219.509
• InChiKey: LKPWGXCMVLJRIK-UHFFFAOYSA-N

物化性质

• 沸点：
  85 °C(Press: 0.1 Torr)
• 密度：
  1.489±0.06 g/cm3(Predicted)
• 闪点：
  110 °C

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

安全信息

• 危险品标志：
  Xn,N
• 安全说明：
  S26,S36/37,S39,S61
• 危险类别码：
  R22
• 海关编码：
  2903999090
• WGK Germany：
  2
• 危险品运输编号：
  UN 3082 9/PG 3
• 包装等级：
  III
• 危险类别：
  9
• 危险性防范说明：
  P264,P270,P273,P280,P301+P312+P330,P305+P351+P338+P310,P332+P313,P501
• 危险性描述：
  H302,H316,H318,H401
• 储存条件：
  室温且干燥环境下使用。

反应信息

• 作为反应物：
  描述：

  3-氯苯乙基溴 在 potassium carbonate 、 sodium iodide 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 168.0h， 生成 JZ-1-96-2-1
  参考文献：
  名称：

  Synthesis and evaluation of orally active small molecule HIV-1 Nef antagonists

  摘要：

  The HIV-1 Nef accessory factor enhances viral replication and promotes immune system evasion of HIV-infected cells, making it an attractive target for drug discovery. Recently we described a novel class of diphenylpyrazolodiazene compounds that bind directly to Nef in vitro and inhibit Nef-dependent HIV-1 infectivity and replication in cell culture. However, these first-generation Nef antagonists have several structural liabilities, including an azo linkage that led to poor oral bioavailability. The azo group was therefore replaced with either a one- or two-carbon linker. The resulting set of non-azo analogs retained nanomolar binding affinity for Nef by surface plasmon resonance, while inhibiting HIV-1 replication with micromolar potency in cell-based assays without cytotoxicity. Computational docking studies show that these non-azo analogs occupy the same predicted binding site within the HIV-1 Nef dimer interface as the original azo compound. Computational methods also identified a hot spot for inhibitor binding within this site that is defined by conserved HIV-1 Nef residues Asp108, Leu112, and Pro122. Pharmacokinetic evaluation of the non-azo B9 analogs in mice showed that replacement of the azo linkage dramatically enhanced oral bioavailability without substantially affecting plasma half-life or clearance. The improved oral bioavailability of non-azo diphenylpyrazolo Nef antagonists provides a starting point for further drug lead optimization in support of future efficacy testing in animal models of HIV/AIDS. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2016.01.043
• 作为产物：
  描述：

  3-氯苯乙酸 在 lithium aluminium tetrahydride 、 三溴化磷 作用下， 生成 3-氯苯乙基溴
  参考文献：
  名称：

  减少微生物的立体化学控制。第31部分：在选定的反应条件下通过面包酵母还原2-氧代-4-芳基丁酸烷基酯

  摘要：

  已证明在水-有机溶剂中用苯甲酰氯处理面包酵母是抑制α-羟基酯还原中提供α-羟基酯的（S）-对映异构体的酶的有效方法。该方法对于全细胞系统生产具有高化学产率和高对映体过量的（R）产物是有效的。

  DOI：

  10.1016/s0957-4166(98)00277-8

文献信息

• 1, 2, 4-Thiadiazol-5-Ylpiperazine derivatives useful in the treatment of neurodegenerative diseases
  申请人：Griffioen Gerard

  公开号：US20140128404A1

  公开（公告）日：2014-05-08

  The present invention relates to a compound of formula (IA) The present invention also relates to the use of the compound of formula IA for treating certain neurodegenerative disorders characterized by cytotoxic TAU misfolding and/or aggregation.

  本发明涉及一种化合物的公式（IA）。本发明还涉及利用公式IA化合物治疗由细胞毒性TAU错误折叠和/或聚集特征的某些神经退行性疾病。
• Novel piperazine derivatives
  申请人：——

  公开号：US20020143020A1

  公开（公告）日：2002-10-03

  The present invention is a chemical compound of formula (I) 1 or a pharmaceutically acceptable salts, solvates and esters thereof, wherein R 1 to R 4 , A 1 , A 2 m and n are as described in the specification.

  本发明是一种具有公式(I)的化学化合物 1 或其药物可接受的盐、溶剂化物和酯，其中R 1 至R 4 ，A 1 ，A 2 ，m和n如说明书中所述。
• Pyridine derivatives and insecticide and miticide comprising said
  申请人：Idemitsu Kosan Co., Ltd.

  公开号：US05262420A1

  公开（公告）日：1993-11-16

  A pyridine compound of the formula ##STR1## wherein X is a hydrogen atom, a halogen atom, an alkyl group having 1 to 4 carbon atoms, an alkoxyl group having 1 to 4 carbon atoms, a haloalkyl group having 1 to 4 carbon atoms or a haloalkoxyl group having 1 to 4 carbon atoms, n is 1 to 5, and when n is 2 or more, Xs may be identical to or different from each other, A is an alkyl residue or alkene residue in which a portion connecting the aryl group with the 4-position of the pyridyl group has 3 to 8 carbon atoms, or an alkapolyene residue in which said portion has 4 to 8 carbon atoms and 2 to 4 double bonds; the alkyl residue, alkene residue, and alkapolyene residue may have an alkyl side chain having 1 to 4 carbon atoms, an alkylidene side chain having 1 to 4 carbon atoms or 1 to 16 halogen atoms, and when there are 2 or more side chains, the side chains may be identical to or different from each other, and R.sup.1 and R.sup.2 are each a hydrogen atom or an alkyl group having 1 to 6 carbon atoms or salts thereof. The pyridine compounds and salts thereof exhibit a strong insecticidal and miticidal activity and are low in residuality and accumulativity and are thus useful as insecticides and miticides for the control of pests in agriculture and horticulture.

  一种杂环化合物，其分子式为##STR1##，其中X为氢原子、卤素原子、1至4个碳原子的烷基、1至4个碳原子的烷氧基、1至4个碳原子的卤代烷基或1至4个碳原子的卤代烷氧基；n为1至5，当n为2个或更多时，X可以相同也可以不同；A为连接芳基和吡啶基4位的部分含有3至8个碳原子的烷基残基或烯基残基，或含有4至8个碳原子和2至4个双键的烯丙基残基；烷基残基、烯基残基和烯丙基残基可以含有1至4个碳原子的烷基侧链、1至4个碳原子或1至16个卤素原子的亚烷基侧链，当存在2个或更多侧链时，侧链可以相同也可以不同；R1和R2各自为氢原子或含有1至6个碳原子的烷基，或其盐。这些杂环化合物及其盐类具有强烈的杀虫和杀螨活性，且残留性和积累性低，因此作为杀虫剂和杀螨剂用于农业和园艺中控制害虫非常有用。
• Novel 1-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-indene-4-thiol derivatives as potent selective human monoamine oxidase B inhibitors: Design, SAR development, and biological evaluation
  作者：Haiyan Kong、Xianshe Meng、Rui Hou、Xiaoxiao Yang、Jihong Han、Zhouling Xie、Yajun Duan、Chenzhong Liao

  DOI：10.1016/j.bmcl.2021.128051

  日期：2021.7

  developing human monoamine oxidase B (hMAO-B) inhibitors as anti-Parkinson’s disease (PD) drugs. However, low efficiency and unwanted side effects of the marketed hMAO-B inhibitors hamper their medical applications, therefore, novel potent selective hMAO-B inhibitors are still of great interest. Herein we report 1-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-indene-4-thiol derivatives as hMAO-B inhibitors, which

  在开发人类单胺氧化酶 B (hMAO-B) 抑制剂作为抗帕金森病 (PD) 药物方面取得了成功。然而，市售 hMAO-B 抑制剂的低效和有害副作用阻碍了它们的医疗应用，因此，新型有效的选择性 hMAO-B 抑制剂仍然很受关注。在此，我们报告了 1-(prop-2-yn-1-ylamino)-2,3-dihydro-1 H -indene-4-thiol 衍生物作为 hMAO-B 抑制剂，它们是通过采用基于片段的药物设计策略设计的将雷沙吉兰与疏水片段连接起来。在合成的 31 种化合物中，K8和K24表现出非常令人鼓舞的 hMAO-B 抑制活性和对 hMAO-A 的选择性，优于雷沙吉兰和 safinamide。体外研究表明K8和K24对神经组织细胞无毒，它们对 ROS 形成和潜在的神经保护活性有相当大的作用。进一步的小鼠行为试验表明，这两种化合物对 MPTP 诱导的 PD 模型小鼠具有良好的治
• NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES
  申请人：Hoffmann-La Roche Inc.

  公开号：US20130137676A1

  公开（公告）日：2013-05-30

  The invention relates to a compound of formula (I) wherein A and R 1 to R 3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

  这项发明涉及一种化合物，其化学式为（I），其中A和R1至R3的定义如描述和权利要求中所述。化合物的化学式（I）可用作药物。

表征谱图